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1. Introduction 
The proper functioning of the central nervous system (CNS) depends on the physiological 
homeostasis, which is itself maintained and regulated by two opposite forces acting 
independently to each other, flowing into a natural cycle and always seeking the balance. 
The thing is about two main amino acid neurotransmitters, glutamate and GABA, creating 
the opposite excitatory/inhibitory forces in the brain. Together, these two neurotransmitters 
constitute more than 90% of all neurotransmission, leaving less than 10% for the others. 
Therefore, to all the possibilities their mutual interaction determinates the proper 
functioning of the CNS. In Fig. 1, the schematic balance is presented, which mirrors the 
physiological equilibrium between GABA (represented by the white dots) and glutamate 
(represented as the black dots). 
 
 
Fig. 1. The schematic balance presenting the equilibrium between GABA and glutamate in 
the physiological state and its loss (overactivation of glutamatergic system) in the anxiety 
disorders. 
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A variety of mechanisms keep the inhibitory/excitatory forces on the physiological level in 
the CNS. The disruption of the cycle leads, in consequence, to the advantage of one amino 
acid over another, resulting in psychiatric disorders. In the anxiety disorders that 
inhibitory/excitatory equilibrium is twisted into increased glutamate level, which will be 
discussed in Chapter 4. In this short review we will focus on that group of mental diseases 
in the field of Glu/GABA interactions; the insight into mechanisms of possible therapy will 
also be presented. 
2. Glutamate-GABA turnover 
The circle of GABA/Glu transformations is closed in the tripartite synapse, with no 
beginning and no end, as schematically shown in Fig. 2. In physiological conditions,  the  
GABA vesicle content is in dynamic equilibrium with intraterminal glutamate 
concentrations (Mathews & Diamond, 2003).  
 
 
Fig. 2. The schematic presentation of glutamatergic-GABAergic transformation involving 
the pyramidal neuron, GABAergic interneuron and astrocyte. Glu-glutamate; GABA-Ǆ 
amino butyric acid; GS-glutamine synthetase; GAD-glutamate decarboxylase; GDH-
glutamine dehydrogenase; GAT-1-GABAergic transporter 1; EAAT-2-excitatory amino acid 
transporter 2; A-system A transporters; N-system N transporters 
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Glutamate is synthesized in neurons in the tricarboxylic acid circle (Liang et al., 2006) as 
well as in the glutamate-glutamine (GLX) cycle, which constitutes as an exogenous source of 
the neurotransmitter. In this cascade of events, glutamate, released from the presynaptic 
neuronal element, is transported to astrocyte through the EAAT-2 transporter. In the 
astrocyte, glutamine synthetase converts glutamate into glutamine, which is then 
transported into extracellular space through system N transporters, and is retrieved by the 
neuronal system A of amino acid transporters (Chaundhry et al., 2002). In neurons (both 
GABA and glutamatergic), glutamine is converted to glutamate in a reaction that is 
catalyzed by phosphate-activated glutamine dehydrogenase. In GABAergic inhibitory 
neurons glutamate further  is converted into GABA by decarboxylation catalyzed with 
glutamic acid decarboxylase (GAD) (Liang et al., 2006). The inhibitory amino acid is then 
metabolized by transaminase to succinic semialdehyd and succinic acid, which re-enters the 
Kreb’s cycle and is transformed into glutamate; the glutamate is released and uptaken by 
the astrocyte, and that closes up the cycle.  
In the properly functioning CNS the release of neurotransmitters, and the 
neurotransmitters’ effects evoked on target neuron is mediated by specific receptors. 
3. Glutamate and GABA receptors 
The neurotransmitter receptors of amino acids are split into several types, most broadly 
demarcated as ionotropic and metabotropic. Ionotropic receptors constitute as 
transmembrane ion channels that open or close in response to the binding of a ligand. These 
receptors convert the chemical signal of a presynaptically released neurotransmitter directly 
and very quickly into a postsynaptic electrical signal (Olsen & Sieghart, 2008), inducing the 
inhibitory postsynaptic potentials (IPSPs) or excitatory postsynaptic potentials (EPSPs), thus 
inhibiting or activating the neuron. Until now, two ionotropic receptors for GABA (GABAA 
and GABAC) and three types of ionotropic receptors for glutamate (AMPA, KA, NMDA) 
have been discovered (Niswender & Conn, 2010; Olsen & Sieghart, 2008). The pharmacology 
of anxiety has been focused on GABAA receptors as the main site of action of ligands with 
anxiolytic activity. Type A of the GABA receptor is composed of five subunits of ligand-
gated protein forming a pore selective to Cl- anions.  The subunits of the GABAA receptor 
constitute a relatively large family of several classes, including their splice variants (ǂ1-ǂ6; 
ǃ1-ǃ4; Ǆ1- Ǆ3, ǅ, ǆ, Θ, ρ1- ρ3).  It enables the formation of a variety of combinations of 
specific subunits within the receptor, thus making it sensitive, or insensitive, to 
pharmacological manipulations (Millan, 2003; Olsen & Sieghart, 2008). Generally the 
receptor is a pentamer consisting of ǂ, ǃ and Ǆ subunits in different combinations, and 
contains sites for the action of various endogenous and exogenous substances, such as 
neurosteroids, bicuculine, muscimol, benzodiazepines, ethanol, barbiturates and GABA 
(Olsen & Sieghart, 2008).    
The NMDA receptor, one of the ionotropic receptors for glutamate, is both a ligand-gated 
and voltage-dependent heterotetrameric ion channel, consisting of two NR1 and two NR2 
subunits (Conti et al., 1999). Activation of the receptor results in the opening of the non-
selective channel to the cations. The receptor, similarly to GABAA, possesses a variety of 
binding sites, such as the polyamine modulatory binding site, the Zn2+ modulatory binding 
site, glycine, glutamate, NMDA, MK-801 and phencyclidine binding sites (Danysz & 
Parsons, 1998). The schematic representation of GABAA and NMDA receptors with the most 
important binding sites present on each of them are shown on Figs. 3 and 4.   
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Fig. 3. The schematic representation of ionotropic (GABAA) and metabotropic (GABAB) 
receptors for GABA. The five subunits of GABAA and their binding sites are shown on the 
left and the GABAB heterodimer composed of BR1 (binding a ligand) and BR2 (coupled to G 
proteins and possessing the allosteric binding site, but not binding the ligand) is shown on 
the right. 
 
 
Fig. 4. The schematic representation of ionotropic (NMDA) and metabotropic (mGluR) 
receptors for glutamate. The four subunits of NMDA (NR1-NR2) and their binding sites are 
shown on the left and the mGlu homodimer composed of two identical parts of the mGlu 
receptor is shown on the right. Two orthosteric binding sites must bind a ligand to activate 
the receptor. An allosteric binding site is present within the 7 transmembrane domain. 
By contrast, metabotropic receptors are connected with second messenger systems and exert 
a rather modulatory role in the CNS (Parmentier et al., 2002). Glutamatergic and GABA 
metabotropic receptors are linked to the G-proteins system and, opposite to the ionotropic 
ligand-gated channels, their action is slow and long-lasting (Bockaert et al., 2010). These 
receptors do not form an ion channel pore, although indirectly they can be linked to ion 
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channels through signal transduction mechanisms that induces the opening or closing of the 
channels (Ango et al., 2000). Metabotropic receptors on the presynaptic membrane can 
inhibit or, more rarely, facilitate neurotransmitter release from the presynaptic neuron 
(Schmitz et al., 2001). There is one metabotropic receptor for GABA (GABAB receptor) 
(Froestl, 2011) and 8 metabotropic receptors for glutamate (mGlu) (Pin and Duvoisin, 1995; 
Niswender & Conn, 2010). mGlu receptors are divided into three classes according to  the 
sequence homology, pharmacology and the second messenger system they activate. The 
schematic classification of mGlu receptors is shown in Table 1.  
The typical G protein-coupled receptor consists of seven hydrophobic transmembrane 
domains linked with extra- and intracellular loops, with the N terminus located on the 
extracellular side of the membrane and C terminus on the intracellular side (Parmentier et 
al., 2002). Both GABAB and mGlu receptors belong to the III family of the G protein-coupled 
receptors (GPCRs). The characteristic feature of this class of receptors is the forming of 
obligatory, functional dimers, possessing a large extracellular ligand-binding domain which 
closes up  like a venus-flytrap after binding a ligand (Figs. 3 and 4) (Pin  Duvoisin, 1995; 
Niswender & Conn, 2010; Bockaert et al., 2010). 
 
 
mGluR 
Group I 
positively coupled to  
phosphatydylo inosytol 
mGluR1 a, b, c, e 
mGluR5 a, b 
Group II 
negatively coupled to adenylyl  
cyclase activity 
mGluR2  
mGluR3  
Group III 
negatively coupled to adenylyl  
cyclase activity 
mGluR4 a, b 
mGluR6 a, b, c 
mGluR7 a, b, c, d, e 
mGluR8 a, b, c 
Table 1. The classification of mGlu receptors (Wierońska &Pilc, 2009) 
The ligands of the GABAergic or glutamatergic receptors were shown to possess excellent 
anxiolytic activity (for review see: Pałucha & Pilc, 2007; Froestl, 2011). Below, the hypothesis 
of the possible mechanisms by which ligands of the receptors for two amino acids restore 
the lost in the anxiety inhibitory/excitatory balance in the CNS will be presented . But, 
firstly, a few words on anxiety. 
4. Anxiety 
The pathophysiology of anxiety disorders is a complex phenomenon and to designate one 
direct cause of their origin is almost impossible. However, those disorders recently became a 
serious public problem as a growing percentage of the population is being diagnosed with 
anxiety every year, and it is the most prevalent mental health problem in Europe and the 
United States (Wittchen & Jacobi, 2005). According to the classification of psychiatric 
disorders, the term Anxiety Disorders covers nearly 12 different pathological states (DSM-
V), including panic disorder, generalized anxiety disorders, post-traumatic stress disorder, 
social phobia, specific phobias.  These mentally ill people are then mainly excluded from 
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normal life for months or even years. Therefore, the search for effective and safe medicine is 
one of the  goals of present neuropharmacology. The effectiveness of the drugs depends, 
largely, on the mechanism of their action. Thus, the important thing is to find out the 
functionally disrupted pathways in the CNS leading to neuropsychiatric illnesses and to 
indicate the possible targets for searching new psychotropic drugs. When it comes to 
anxiety disorders, the involvement of different neurochemical pathways were discussed 
during the past few decades.  
Several neurotransmitters mediate the different components of anxiety, including excitatory 
amino acids such as Glu and inhibitory such as GABA. Generally, different aspects of 
anxiety response are mediated by various neurotransmitters in anatomically distinct areas. 
Important for our consideration dynamic balance between inhibitory/excitatory forces in 
the brain is thought to be disrupted with increased excitation leading to anxiousness. An 
increase in the glutamate efflux in the prefrontal cortex and hippocampus was observed 
after stress (Moghaddam et al., 1993; Bagley & Moghaddam, 1997). Anxiogenic behavior 
was observed in mice lacking the GAD65, enzyme responsible for converting Glu into 
GABA (Kash et al., 1999). 
5. Present anxiolytics and future perspectives 
In the pharmacological treatment of anxiety, drugs with a different mechanism of action are 
available. These include benzodiazepines, 5-HT1A agonists, and antidepressant 
medications. They all have their advantages and disadvantages, but as the review concerns 
GABAergic and glutamatergic neurotransmission, the compounds involving other 
mechanisms of action will not be discussed here, as they are widely described elsewhere 
(see: Millan, 2003). 
The most efficacious anxiolytic drugs are the positive modulators (PAM) acting at the 
benzodiazepine binding site on the GABAA receptor, thus enhancing the affinity of the 
natural agonist to the receptor, known as benzodiazepines (Sternbach et al., 1974). The 
number of representatives of the group reaches nearly 80, and diazepam is probably the best 
known not only as an anxiolytic, but also as a hypnotic drug. Although the drugs have 
relatively good efficacy, a variety of adverse effects is also described. The most common are: 
ability to induce tolerance, sedation, myorelaxation, and dependence (Millan, 2003). 
Moreover, memory impartment and interaction with alcohol can occur. That is supposed to 
be connected with the activation of the ǂ1 subunit of the GABAA receptor (Esclapez et al., 
1996). The other binding sites of the receptor, such as barbiturates, muscimol or picrotoxin 
(shown on Fig. 3) are even worse drug targets. Although the anxiolytic-like activity of 
benzodiazepines is connected with activation of ǂ2-ǂ3 subunits, the majority of drugs 
activate to some extent the other subunits, too (Gao et al., 1993; Esclapez et al., 1996), thus 
being responsible for variety of adverse effects that may occur.  
The discovery of the metabotropic GABAB receptor brought new possibilities for searching 
agents with the mechanism of action based on the enhancement of GABA transmission. 
Because of the relatively short time since the cloning of the receptor (which was in the year 
1997), the clinically effective drug activating the receptor with anxiolytic efficacy are lacking 
at present; the orthosteric agonist of the receptor, baclofen, introduced in 1977 for the 
treatment of multiple sclerosis (Sachais, 1977), induces a variety of adverse effects including 
sedation and miorelaxation, whilst the anxiolysis was not discussed as an asset of the drug. 
However, in 2000 the first positive modulators of the GABAB receptor were discovered. The 
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preclinical trials were promising as all of the compounds possessed anxiolytic activity and 
were free of adverse side-effects typical for benzodiazepines, such as sedation or 
miorelaxation (Froestl, 2011). Interestingly, the antagonist of GABAB receptors are not active 
as anxiolytics, being rather described as possible antidepressants (Pilc & Nowak, 2005). 
Table 2 summarizes the main classes of the compounds activating GABA receptors, with 
special attention to their anxiolytic efficacy. 
 
GABAA  ligands 
benzodiazepine  site PAMs 
(benzodiazepines) 
GABA transaminase inhibitors (Ǆ-vinyl  
GABA, aminooxyacetic acid) 
GABA reuptake inhibitors (tiagabine) 
GABA agonists (muscimol, THIP) 
ethanol 
neurosteroides 
see: Millan, 2003 
 
Sherif et al., 1994 
 
Schaller et al., 2004 
 
Corbett et al., 1991 
see: Millan 2003 
GABAB ligands 
positive allosteric modulators
(GS39783, CGP7930, CGP13501, NVP-
BHF177, (+)-BHFF)
see: Froestl, 2011 
Table 2. GABAergic ligands with anxiolytic activity. 
Pharmacological investigation of the glutamatergic system had lagged far behind research 
into the GABA systems because of the limitations connected with the use of ionotropic 
receptors ligands. Although some of the compounds acting at the NMDA and AMPA 
receptors were shown to possess anxiolytic activity, the adverse effects after the 
administration of antagonists of those receptors, such as the psychotomimetic effects and 
influence on locomotor activity were observed (Danysz & Parsons., 1998). The narrow 
window between therapeutic doses and doses inducing adverse effects caused a quick end 
to the therapeutic hopes connected with that receptor. However, it did not shatter the 
glutamatergic system as a target for anxiolytic drugs. A few clinical trials showed that some 
commonly used medications were found to exert their therapeutic effect by modulating 
glutamatergic transmission (via the inhibition of voltage-dependent ion channels). 
Additionally, these compounds were shown to be effective in anxiolytic disorders in 
randomized, double-blind, placebo-controlled trials (Table 3).  
 
Compound Anxiolytic activity tested in the clinic 
Pregabalin 
Topiramate 
Lamotrigine 
Riluzole 
Tiagabine 
Valproic acid 
Phenytoine 
Gabapentin 
Levetiracetam 
D-cycloserine 
generalized anxiety disorder 
post-traumatic stress disorder, specific phobias 
post-traumatic stress disorder 
generalized anxiety disorder 
generalized anxiety and post-traumatic stress disorder 
panic disorder, social phobia  
post-traumatic stress disorder 
social phobia 
specific phobias, panic disorder 
post-traumatic stress disorder, phobia 
Table 3. Examples of anxiolytic-like activity of agents modulating glutamatergic activity 
(Amiel &Mathew, 2007). 
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The discovery of metabotropic glutamate receptors opened a broad range of possibilities to 
modulate the glutamatergic system. They became a target for putative anxiolytics, including 
antagonist, agonist or modulators (depending on the type of receptor they bind). A variety 
of subtypes involving different second messenger systems, with an expression in all of the 
brain regions both post- and presynaptically as auto– and heteroreceptors, make those 
receptors a very attractive therapeutic target. A number of preclinical studies clearly 
indicated that ligands of those receptors are excellent anxiolytics (Pałucha & Pilc, 2007; 
Wieronska & Pilc, 2009). Especially interesting agents were found among antagonists of the 
first group and agonists of the second group of mGlu receptors (Wieronska & Pilc, 2009). 
The clinical studies, which started in early ‘90s of the last century with fenobam, a drug with 
a mechanism of action that was unknown at the time, revealed that the compound was 
evidently effective as a novel, non-benzodiazepine anxiolytic (Porter et al., 2005). Today, we 
know that the drug is a negative allosteric modulator of the mGlu5 receptor. Similarly,  the 
mGlu2/3 agonists have undergone positive clinical trials, such as LY354740 and its 
derivative, LY544344 (Dunayevich et al., 2008).  
 
NMDA ligands 
NMDA channel blockers (memantine, MK-
801) 
competitive antagonists (L-AP4, L-AP7, 
MDL100453, CGP37849, CGP39551, 
NPC17742)  
inverse agonists (ACPC) 
glycine site antagonists (5,7 dichlorokinurenic 
acid, L 701324)
see: Danysz &Parsons, 1998 
AMPA ligands 
antagonists (LY326325, LY382884, LY293558)
2,3 BZD AMPA site antagonists (GYKI52466, 
GYKI53404, GYKI53655, EGIS8332, EGIS9637, 
EGIS10608)
Alt et al., 2007 
Kapus et al., 2008 
mGlu ligands 
mGluR1 antagonist (JNJ16259685, AIDA, 
LY456236, EMQMCM) 
mGlu5 NAMs (MPEP, MTEP) 
mGlu5 antagonist (fenobam) 
mGlu2/3 agonists (LY 354740, LY 314582, LY 
544344, LY 404039, LY 379268 ) 
mGlu2 PAMs (4-APPES, CBiPES, BINA, 
LY487379) 
mGlu2/3 antagonists (MGS0039, LY341495) 
mGlu4 agonist (LSP1-2111,    ACPT-I) 
mGlu7 PAM (AMN082) 
see: Wierońska &Pilc, 2009 
 
see: Pałucha &Pilc, 2007 
Porter et al., 2005 
Linden et al., 2005, 2006; 
Dunayevich et al., 2008 
see: Wierońska &Pilc, 2009 
 
Iijima et al., 2007 
Stachowicz et al., 2008, 
2009, Wierońska et al., 2010  
Table 4. Glutamatergic receptors ligands with anxiolytic activity. 
The third group of mGlu receptors is the biggest one and has been the least investigated so 
far, mainly because of the lack of selective and brain-penetrating agents. ACPT-I was the 
first brain penetrating compound, activating both mGlu4 and mGlu8 receptors. The 
compound exerted an anxiolytic-like efficacy in rodents (Stachowicz et al., 2009). Later on, a 
more selective compound, LSP1-2111 was synthesized, and was shown to preferentially 
activate mGlu4 receptors. Anxiolytic-like activity was described after the administration of 
relatively low doses (Wieronska et al., 2010 ). The glutamatergic receptors ligands with 
anxiolytic activity are listed in Table 4. 
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Taken all together it appears that, as stated above, both glutamatergic and GABAergic 
agents may evoke anxiolysis, mainly through agonistic action. Below  the mechanism of 
action of those ligands will be introduced with an indication of a common direction of action 
leading to inhibition of the excessively active glutamatergic system.  
6. Mechanism of action of GABAergic agents 
The involvement of the GABAergic system, in particular the action of GABAmimetics 
stimulating GABA receptors, such as benzodiazepines, is a certainty in the present 
neuropharmacology of anxiety.  The general mechanism of action of those compounds is an 
enhancement of GABAergic neurotransmission in the brain, which is tantamount to the 
enhancement of inhibition; however, the point is not in the inhibition per se but, rather, in 
the cascade of events caused by the inhibition.  
As was mentioned above, GABA acts through three different types of receptors. As the 
pharmacology of the ionotropic GABAC receptor is the least investigated at present, we will 
focus on the mechanism of action of the ligands of two others: the ionotropic GABAA and 
metabotropic GABAB receptor (Froestl, 2011). Activation of both receptors causes an 
inhibition of neuronal excitability. However, what it means exactly depends on the 
expression of these receptors on the type of neuron. 
6.1 GABAA signaling 
Typical anxiolytic drugs, benzodiazepines, act by enhancing the inhibitory effects of GABA 
at GABAA receptors containing either an ǂ1, -2, -3 or -5 subunit. Postsynaptic expression of 
GABAA receptors composed of responsible for the anxiolytic-like efficacy ǂ2 - ǂ3subunits 
was shown mainly on GAD-positive neurons, that is GABAergic interneurons (Gao et al., 
1993; Esclapez et al., 1996). Therefore, activation of those GABAA receptors [see Fig.5 (1)] 
would inhibit the GABAergic neurotransmission. Moreover, such an inhibition would, in 
turn, exert anxiolysis only indirectly, possibly through the disinhibition of the GABAergic 
projection neuronal element, increasing an inhibitory action on pyramidal target neurons. 
The described mechanism is supposed to be responsible for inhibiting glutamatergic 
neurons in structures mediating anxiolytic response, such as the lateral amygdala (Rainnie e 
al., 1991), and medial prefrontal cortex (mPFC) (Gigg et al., 1994). 
  
 
Fig. 5. The schematic neuronal network showing the mechanism of the postsynaptic action 
of the GABAA agonist, diazepam (see description in the text). empty dots- GABA; black 
dots-Glu; (-)-inhibition; (+)-enhancement; the number of dots indicates the amount of 
neurotransmitter released 
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The GABA released from inhibitory interneurons, and GABAmimetics administered 
exogenously, may also inhibit the glutamatergic pyramidal neurons via GABAA receptors 
expressed on the dendrites and soma of pyramidal neurons [see:Fig.5 (2)]. The activation of 
these receptors would directly lead to the inhibition of excitatory amino acid 
neurotransmission, as was shown in the electrophysiological studies on IPSPs in the 
glutamatergic neurons of the basolateral amygdala (BLA) (Chhatwal et al., 2005), as well as 
in the pyramidal cells of the piriform cortex and hippocampus (Samulack et al., 1993; Kapur 
et al., 1997).   
Although the inhibitory effect of GABA mediated through the GABAA receptor is commonly 
considered to be postsynaptic, the presynaptically expressed GABAA receptors were also 
described in the variety of neurons in the CNS; however, the pharmacological properties of 
those receptors are relatively poorly understood. Mossy fibers in the hippocampus 
representing the axons of granule cells constitute one of the sites of the presynaptic 
expression of GABA receptors (Jang et al., 2006). Activation of these receptors induces 
neuron depolarization and facilitates spontaneous glutamate release (Jang et al., 2006). The 
standard anxiolytic drug, diazepam, was shown to induce an increase in the frequency of 
EPSPs and the potentiation of muscimol-induced glutamate release (Han et al., 2009).  
Although at first sight the effect may seem paradoxical, it may fit the theory of diazepam-
mediated anxiolysis when considered through a variety of histological and 
electrophysiological data. The axons of granule cells synapse with a wide variety of 
inhibitory GABA interneurons in the hilar region of the dentate gyrus before continuing on 
to innervate pyramidal cells in the CA3 region. Therefore, the increased glutamate release 
by presynaptically active diazepam [see: Fig.6 (1)] would activate GABAergic interneurons 
which would then go on to inhibit increased excitation and thus lead to anxiolysis. 
Therefore, the circle closes up as the excitation leads to inhibition and inhibition inhibits the 
excitation. 
 
 
Fig. 6. The schematic neuronal network showing the mechanism of the presynaptic action of 
the GABAA agonist, diazepam (see description in the text). empty dots- GABA; black dots-
glu; (-)-inhibition; (+)-enhancement; the number of dots indicates the amount of 
neurotransmitter released 
6.2 GABAB signaling 
As an alternative to the ionotropic GABAA receptor, there is the GABAB  receptor that is 
capable of exerting the slow and modulatory action of inhibitory neurotransmission, often in 
close association with the GABAA pentamer (Kardos et al., 1994). Similar to the above 
described ionotropic channel, the GABAB receptor was shown to be expressed both pre- and 
postsynaptically. Presynaptically expressed heterodimers are generally composed of 
GABAB1A/GABAB2 subunits, while postsynaptic neurotransmission is mediated by the  
GABAB1B/GABAB2 tandem (Billinton et al., 1999). 
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The GABAB receptor has only been cloned relatively recently, so the well documented 
clinical trials concerning the anxiolytic activity of its ligands are poorly available. However, 
based on the electrophysiological, histochemical and behavioural studies presenting its 
ability to balance the excitatory/inhibitory forces in the CNS, it is very likely that it may 
become a promising target in the search for novel anxiolytics. In the hippocampal slices, the 
subpopulation of interneurons was selected that inhibits pyramidal cells via GABAB 
postsynaptic receptors (Samulack et al., 1993; Forti et al., 1997), independently on GABAA 
signalling. Therefore, pharmacological stimulation of the GABAB receptor on  pyramidal 
neurons would exert the inhibitory effect on glutamatergic transmission, thus inducing 
anxiolytic efficacy [see: Fig. 7 (2)].  
Besides the inhibitory influence on pyramidal cells, GABAB–mediated inhibition was also 
observed on inhibitory interneurons, when measured with whole cell patch-clamp techniques 
(Mott et al., 1999). Pharmacological stimulation of these receptors would inhibit the inhibition 
[see: Fig.7 (1)]. As described for GABAA receptor activation, such action exerts anxiolysis only 
after the disinhibition of  GABAergic network innervating target pyramidal neurons. 
  
 
Fig. 7. The schematic neuronal network showing the mechanism of the postsynaptic action 
of the GABAB receptor positive allosteric modulator, GS39783 (see description in the text). 
empty dots- GABA; black dots-Glu; (-)-inhibition; (+)-enhancement; the number of dots 
indicates the amount of neurotransmitter released 
The speculation on the mechanism of putative anxiolysis mediated by activation of the 
GABAB receptor does not end on the postsynaptic effects. Heterodimers were shown to be 
localized presynaptically along the extrasynaptic plasma membrane of axon terminals and 
along the presynaptic active zone in both asymmetrical and, to a lesser extent, symmetrical 
synapses (Lopez-Bendito, 2004). The fundamental role of these receptors is the inhibition of 
the release of the neurotransmitter [see: Fig.7 (3)]. The majority of presynaptically expressed 
GABAB heteroreceptors was found on the glutamatergic nerve terminals. The activation of 
these receptors would inhibit the excitatory amino acid release, resulting in anxiolysis.  
7. Mechanism of action of glutamatergic agents 
The vast diversity of receptors for glutamate creates a variety of possibilities to influence 
both excitation and inhibition in the brain. The age of glutamate began with the discovery of 
metabotropic glutamate receptors in 1986, which shortly became a promising alternative to 
iGlu receptors in a variety of investigations in the field of neuropharmacology (Nicoletti et 
al., 1986). Presently, the important role of mGlu receptors in anxiety is almost unquestioned 
and their role as the important anxiolytic drug targets is well established. However, the role 
of ionotropic receptors, NMDA and to some extent AMPA, is still significant despite the 
limitations connected with adverse effects induced by their ligands. The expression of the 
receptor was detected on dendritic terminals of glutamatergic neurons and interneuronal 
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post-synaptic sites, thus influencing the firing of both inhibitory and excitatory projections 
(Conti et al., 1999; Standaert et al., 1999; Ratzliff et al., 2001). The variety of different 
combination of NR1-NR2 subunits results in the existence of the diversity of receptor 
variants, expressed differently on a subpopulation of neurons and affecting  function and 
selective vulnerability (Landwehrmeyer et al., 1995; Standaert et al., 1999). It creates a 
potential for altering the balance of inhibition and excitation independently in selected parts 
of the brain. For example, in the amygdale, the structure known as the responsible for 
storage of fear memories, NMDA, composed of NR1-NR2B subunits, was shown to be 
expressed mainly in the synapses of the central nucleus, while in the lateral nucleus the 
receptor contains both NR2A and NR2B subunits (Sah et al., 2003). It remains open for 
further investigation whether or not it has some functional meaning. 
As was mentioned above, the iGlu receptors will not be discussed here as a putative target 
for new drugs. However, it is worth mentioning that the blockers of the NMDA receptor 
were shown to possess anxiolytic-like activity. One of the compounds, memantine, was 
effective in humans and has undergone successful clinical trials (Aboujaoude et al., 2009). In 
the preclinical studies, the antagonists of the second iGlu receptor, AMPA, exerted 
anxiolytic-like efficacy as well, supporting the important role of the iGlu receptors in anxiety 
(Kapus et al., 2008). The AMPA expression was predominantly found on pyramidal cells 
and interneurons, among others in the amygdale, known for its role in stress response (Sah 
et al., 2003). To all the possibilities the action of memantine is mediated via the NMDA 
receptor localized postsynaptically on inhibitory interneurons. Blockade of those receptors 
by the antagonist [see: Fig.8 (1)] would inhibit the GABAergic tone which would contribute 
to the stimulatory effect on inhibition followed by the inhibition of excitation. 
This experimental data clearly shows that the blockade of the receptors exerts anxiolytic 
function. In the physiological conditions, the endogenous antagonists are not available or, at 
least, are not identificable, so the activity of the receptors is regulated predominantly by the 
glutamate. The level of amino acid regulates both the anxiety state and the anxiolytic response. 
As the iGlu receptor was shown to be expressed by the postsynaptic membrane of pyramidal 
neurons, the increased level of glutamate would lead directly to depolarization of the neuron 
and the activation of glutamatergic network activity, inducing an elevated stress response. 
Therefore, the anxiolysis could be induced by decreasing the level of endogenously released  
glutamate. Diminished glutamate release would activate the NMDA receptor to a lesser 
degree and the excitation of the CNS would remain at a stable level. Such an effect can be 
achieved by switching on the regulatory machinery of presynaptic glutamate release. mGlu 
receptors contribute to the effect, being the most important pawns in the circle. 
 
 
Fig. 8. The schematic neuronal network showing the mechanism of action of the NMDA 
receptor antagonist, memantine (see description in the text). empty dots- GABA; black dots-
Glu; (-)-inhibition; (+)-enhancement; the number of dots indicates the amount of 
neurotransmitter released 
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Below, step by step, the possible mechanisms of the anxiolytic-like efficacy of metabotropic 
glutamate receptor ligands will be described, paying special attention to the excellent 
regulatory action exerted by the II and III group of the receptors both in asymmetrical and 
symmetrical synapses. The dynamically changing synaptic cleft environment and the 
amount of available neurotransmitters are dependent on their proper functioning. By 
contrast to the II and III groups of the receptors, the representatives of the first group tend to 
mediate the postsynaptic action which itself mediates the slow excitatory current (Pin & 
Duvoisin, 1995). From this group our deliberations start. 
7.1 Group I mGlu receptors 
Although the first group of receptors is predominantly distributed on the post-synaptic 
parts of the neurons, the presynaptic localization was also described.  
The ligands of these receptors, especially the antagonists of the mGlu5 subtype, were shown 
to possess profound anxiolytic activity. A variety of preclinical experiments with negative 
allosteric modulators of the receptor, MPEP and MTEP, were further confirmed in the 
clinical studies, when fenobam, a mGlu5 antagonist, was first described as the non-
benzodiazepine anxiolytic drug (see: Pałucha&Pilc, 2007; Porter et al., 2005).   
The antagonistic action of MPEP, and probably other ligands acting at the mGlu5 receptor, 
results in the inhibition of stimulated DHPD PI hydrolysis and the neuronal firing in the 
CA1 area of the hippocampus (Kuhn et al., 2002), generally inducing the inhibition of the 
target cell.  Immunohistochemical studies at the electron microscopy level indicate that 
mGlu5 receptors form functional oligoheteromers with NMDA receptors, and the group of 
Homer proteins is responsible for coupling mGlu5 with NMDA (Ango et al., 2000). 
Electrophysiological and biochemical studies confirm the functional dependence between 
these two receptors, as the NMDA-mediated current and NMDA-induced increase in the 
CREB phosphorylation were reduced by MPEP (Lindemeyer et al., 2006). The above 
findings characterize the inhibitory nature of the mGlu5 antagonists. However, the 
mechanism of the anxiolytic-like efficacy of the compounds involves the target neuronal 
elements expressing the receptor. Based on electrophysiological and immunohistochemical 
data, mGlu5-NMDA complexes are expressed predominantly on the inhibitory interneurons 
in the hippocampus (Sanon et al., 2010), cortex (Sarihi et al., 2008) or amygdala. As such, it 
would appear that the MPEP-induced inhibitory action on GABAergic interneurons is 
responsible for its anxiolytic effect [see: Fig.9 (1)]. This inhibition of the  inhibition results in 
 
 
Fig. 9. The schematic neuronal network showing the mechanism of action of the MPEP, 
mGlu5 receptor antagonist (see description in the text). empty dots- GABA; black dots-Glu; 
(-)-inhibition; (+)-enhancement; the number of dots indicates the amount of 
neurotransmitter released 
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a rich repertoire of changes which take place the synapses between interneurons and 
pyramidal neurons to induce feedback inhibition of increased excitation. Indeed, as 
microdialysis studies indicate that the level of glutamate, yet not GABA, is decreased after 
MPEP administration, at least in periagueductal gray, one of the structures involved in 
anxiety response (de Novellis et al., 2003). 
Although it seems that anxiolysis induced by mGlu5 antagonists is mediated mainly 
through their action at the postsynaptic site, the presynaptic expression of group I mGlu 
receptors was also described. mGlu5 labelling at axon terminals was not so intensive as on 
neuronal somata, but was observed in some glutamatergic axonal terminals (Rae et al., 
2004).  The blockade of these receptors would inhibit the release of glutamate, causing 
anxiolytic response [see: Fig.9 (2)]. 
7.2 Group II mGlu receptors 
The second group of metabotropic glutamate receptors involves mGlu2 and mGlu3 
subtypes, negatively stimulating adenylyl cyclase activity (Niswender & Conn, 2010).  The 
majority of the agonist and positive modulators of these receptors possess excellent 
anxiolytic efficacy. Among the available ligands it is hard to find one not showing such 
activity in the preclinical studies. As the agonists mostly activate both subtypes of the 
receptors, the estimation of the independent participation of each subtype in anxiolysis is 
difficult. Selective positive modulators of the mGlu2 subtype exert anxiolytic-like efficacy 
indicating the important role of the receptor in mGlu2/3 agonist-mediated anxiolysis. 
However, the role of the second subtype is more enigmatic because of the lack of selective, 
brain penetrating agents acting on the mGlu3 subtype. Some indirect conclusion can be drawn 
on the basis of the results obtained with the use of mGlu2 knockout mice. The majority of 
effects observed after administration of mGlu2/3 agonists were lacking in these animals, 
suggesting the mGlu2-dependent action of ligands (Linden et al., 2006; Woolley et al., 2008). 
Although some controversial results showing the involvement of the mGlu3 receptor in 
mGlu2/3-mediated anxiolysis can also be found (Linden et al., 2005), the activation of the 
mGlu2 receptor seems to be crucial for mGlu2/3 agonists-mediated anxiolysis. 
Among all of the mGlu receptor subtypes located in structures connected with fear 
response, mGlu2 receptor seems to be expressed predominantly on glutamatergic terminals, 
in pre-terminal rather than terminal portions of the axons (Petralia et al., 1996; Shigemoto et 
al., 1997). The expression of the mGlu2 receptors, as shown in the diagram, suggests that 
activation of the receptor occurs during abnormal and elevated glutamate release, allowing 
the neurotransmitter to regulate its own release. As the receptors are not in close association 
with glutamatergic synapses and a subpopulation of the receptors not associated with any 
synaptic junction was identified, the receptor can be probably activated by glutamate of a 
nonsynaptic origin. The astrocytes constitute the main source of this additional glutamate 
pool in the CNS [as shown on Fig.10]. The glutamate released by single astrocyte onto 
adjacent neuronal processes controls simultaneously the excitability of several neighboring 
pyramidal cells  (Angulo et al., 2004), and the mGlu2 receptor could play an important role 
in this process. Besides this, a growing line of evidence indicates that glutamate is able to 
escape the synapse from which it is released and diffuse into neighboring junctions to 
activate receptors there (Diamond, 2002). The occurrence of this type of heterosynaptic 
inhibition was demonstrated at mossy fibre synapses in the hippocampus (Vogt & Nicoll, 
1999), the place where there is rich mGlu2 innervation (Petralia et al., 1996). Exogenously 
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administrated compounds acting on these receptors would restore the twisted 
excitatory/inhibitory balance independently on synaptic machinery, playing the supportive 
role in the self-regulating circle, which can itself be disrupted in a pathological state.  
 
 
Fig. 10. The schematic neuronal network showing the mechanism of the action of mGlu2/3 
receptor agonist, LY379268 (see description in the text). empty dots- GABA; black dots-Glu; 
(-)-inhibition; (+)-enhancement; the number of dots indicates the amount of 
neurotransmitter released. 
By contrast to group I and group III mGlu receptors (which will be discussed later), mGlu2 
agonists directly inhibit glutamatergic neurotransmission, in majority not involving any other 
neurotransmission systems via presynaptic blockade of glutamate release [see: Fig.10 (1)].  In 
electrophysiological studies, a direct inhibition of projecting basolateral neurons, and the 
reduction of the excitatory drive were observed after administration of LY354740 and 
LY379268, mGlu2/3 receptor agonists (Muly et al., 2007). The inhibitory effect on stimulated 
glutamate release was also observed in microdialysis studies (Xi et al., 2002; Johnson et al., 
2005).  
However, some studies indicate that the release of GABA in the hippocampus stays under 
inhibitory control of group II mGlu receptors expressed on GABAergic terminals [see: Fig.10 
(2)] (Kogo et al., 1999). If this regulatory action on inhibition contributes to anxiolysis, the 
intermediary interneuron innervating pyramidal glutamatergic target cells must be 
disinhibited. 
7.3 Group III mGluR 
The third group of metabotropic glutamate receptors constitutes the largest family and 
involves mGlu4, mGlu6, mGlu7 and mGlu8 subtypes. The most important for our 
consideration are mGlu4 and mGlu7 representatives, as the ligands of these receptors 
exerted clear anxiolytic action. mGlu6 expression is restricted mainly to the retina (Laurie et 
al., 1997) and the mGlu8 selective and brain-penetrating ligands have been poorly available 
so far. The studies concerning the recently synthesized positive allosteric modulator of the 
receptor, AZ12216052, indicate that stimulation of the receptor could result in anxiolysis 
(Duvoisin et al., 2010). 
Expression of the group III mGlu receptors subtypes is distinct and somewhat 
complementary throughout the structures involved in anxiolysis. The receptors are, above 
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all, presynaptic and are usually located close to the center of the synaptic cleft. The receptors 
show a highly selective expression and subcellular location on nerve terminals modulating 
neurotransmitter release.  Contrary to the other described presynaptic auto- or 
heteroreceptors, the stimulation of the receptors of the third group decreases not only 
vesicular and non-vesicular glutamate release (Xi et al., 2003), but also depresses the release 
of GABA from interneurons (Rusakov et al., 2004).   
The mGlu4 receptor can act as autoreceptor expressed by glutamatergic terminals or as the 
heteroreceptor localized on GABAergic axons, suggesting the role of the mGlu4 receptor in 
in the regulation of both types of neurotransmitter (Corti et al., 2002). The excitatory input to 
the hilar-dentate border of the interneurons was depressed after mGlu4 receptor activation 
(Doherty & Dingledine, 1998). This may result in the disinhibition of GABA-releasing 
terminals that innervate the principal cells [see: Fig.11 (1)], thus inhibiting glutamatergic 
network. 
The presence of mGlu4 receptors on hippocampal interneuronal terminals projecting from 
the hilus was also described, and with the use of electrophysiology it was shown, that  they 
innervate the other GABAergic postsynaptic element [see: Fig.11 (2)] (Kogo et al., 2004). The 
source of excitatory amino acid in this kind of GABA-GABA synapse may come from 
glutamate spillover, allowing for the heterosynaptic regulation of the functional 
excitatory/inhibitory network. The disinhibition of the postsynaptic interneuron would 
regulate the activity of target glutamatergic cells. 
Among all of the mGlu group III receptors, mGlu4 receptor revealed a relatively high level 
of post-synaptic staining, confirmed both in light and electron microscopy studies on 
pyramidal neurons in the some areas of the hippocampus (Bradley et al., 1996). Whether the 
anxiolytic-like action of mGlu4 receptor agonists involves the activation of these post-
synaptically expressed receptors, however, still remains open for discussion. 
The other candidate for regulating the glutamate/GABA level in the CNS is the mGlu7 
receptor, widely distributed through the CNS, in the pre-synaptic grid, at the site of the  
synaptic vesicle fusion (Shigemoto et al., 1996). The axon terminals expressing the mGlu7 
receptor were observed to be concentrated densely and specifically on mGluR1ǂ-like 
immunoreactive GABAergic interneurons [see: Fig.11 (3)] (Shigemoto et al., 1996; Kinoshita 
et al., 1998). Therefore, the final result of the pre-synaptic action of the activated mGlu7 
receptor is modulation of the postsynaptic GABAergic target [see: Fig.11 (3)]. This inhibition 
would cause the disinhibition of the other interneurons, targeting the glutamatergic 
network. The pyramidal neurons expressing mGlu7 on their terminals can form synapses 
with dendrites of the pyramidal cells; however, the expression of the mGlu7 receptor was 
found to be almost ten-fold higher in these pyramidal axons that innervate the mGluR1 alfa-
expressing interneurons (Samogyi et al., 2003). Interestingly, mGlu7 receptors are also 
expressed on some types of the interneuron population (e.g VIP positive) innervating 
mGlu1ǂ-somatostatine postsynaptic interneurons [see: Fig.11 (4)] (Dalezios et al., 2002) and 
creating a kind of GABA-GABA synaptic junction. Similar to the one described for mGlu4, 
the mechanism of anxiolysis involves inhibition of the GABA release, and in the simplest 
scenario, the depression of the GABA release could lead to a disinhibition of postsynaptic 
interneuron and increased GABA release on their terminals, inhibiting the input zone to the 
pyramidal cells. However, as the affinity of the mGlu7 receptor to glutamate is very low, in 
these kind of symmetrical GABAergic synapses to all the possibility the receptor is not 
activated by endogenous glutamate. mGlu7 PAM can possibly sensitise the affinity of the 
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receptor to glutamate, leading to anxiolysis.  In rare cases, glutamate and GABA can be 
stored and released by the same nerve terminals (Walker et al., 2001), although in a properly 
functioning brain the glutamate is metabolized to GABA in interneurons. As the impartment 
in GAD67, the enzyme responsible for catalyzing the reaction was described in mood 
disorders and it can be speculated that under pathological conditions the glutamate is 
released by GABAergic interneurons, thus activating presynaptic glutamatergic receptors 
(Kash et al., 1999). 
The distribution of the mGlu8 receptor was observed on the presynaptic active zones of 
neurotransmitter release on identified GABAergic and putative glutamatergic terminals that 
create synapses with several types of GABAergic neurons (Ferraguti et al., 2005). The type of 
the synapse predicts a role in adjusting the activity of interneurons depending on the level 
of network activity, widely described several times before now. The receptor is often 
expressed closely to its mGlu7 relative, therefore its action would involve similar 
mechanisms to those described above. 
 
 
Fig. 11. The schematic neuronal network showing the mechanism of action of the mGlu 
group III receptor agonist LSP1-2111 (mGlu4 agonist) and AMN082 (mGlu7 agonist) (see 
description in the text). empty dots- GABA; black dots-Glu; (-)-inhibition; (+)-enhancement; 
the number of dots indicates the amount of neurotransmitter released 
Reassuming the expression and functional consequences of the group III mGlu receptors 
family it can be concluded, that the receptors are present both on pyramidal and 
interneuronal terminals. The pyramidal neurons expressing mGlu4/7/8 receptors may 
contact with both the interneurons and pyramidal cells, but the GABAergic terminals 
expressing mGlu4, mGlu7 and mGlu8 receptors form the most synapses with the 
interneurons (predominantly mGlu1ǂ-somatostatin positive), yet not with the pyramidal 
cells (Kogo et al., 2004), depressing the IPSCs of the inhibitory neuronal elements. Those 
receptors are activated with the glutamate released by the glia, or heterosynaptically by the 
glutamate released in the neighboring synapse. Such glutamate spillover enables the 
synapse to cooperate in regulating  the excitatory/inhibitory balance in CNS. 
8. Conclusions 
The search for new anxiolytic therapy is one of the key areas of modern research, and a hope 
for the growing number of people affected by anxiety disorder. Besides, the anxiety is 
commonly comorbid with different psychiatric, and somatic, illnesses, so the proper 
treatment can constitute a supplementary therapy. There is no better way to improve 
pharmacological treatment than understanding the complex interaction between 
excitation/inhibition in the CNS.  All that was written in these few pages until now states 
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that the receptors mediating both fast and slow excitatory or inhibitory currents are present 
at a broad range of synapses that are postulated to be critical for the maintenance of the 
correct balance in the brain. The complex interactions between synaptic responses, the 
releases of the neurotransmitters and receptor trafficking (not discussed here) at the 
excitatory glutamatergic or inhibitory GABAergic synapses is more complicated than 
anyone could ever imagine. 
More than one type of auto- heteroreceptor can be expressed on one nerve terminal, so the 
receptors may cooperate with, or antagonize, each other’s action. Such a cooperation has 
already been shown for mGlu7/GABAB receptors. Besides, each type of pyramidal neuron is 
likely to be innervated by multiple, functionally distinct GABA cells, which may differ in the 
mGlu expression. Some other factors, such as variation of the presynaptic receptor level in 
individual terminals or the state of activation or desensitization of the receptor, may also be 
important in the final effect of the treatment.  
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